Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin for outpatient COVID-19
IRCT20111224008507N4Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of ivermectin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Clinical improvement after 6 days and Negative PCR result after 6 days. Started Feb 2021; status: completed.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20111224008507N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20111224008507N4.